# OnCo record capstone-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/capstone-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "capstone-1", "NCT03711305" ;
  schema:name "CAPSTONE-1"@en ;
  schema:description "The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease."@en ;
  schema:url <https://onco.cc/trials/capstone-1/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03711305>, <https://doi.org/10.1016/S1470-2045(22)00224-8> ;
  onco:status "positive" ;
  onco:tag "china" ;
  onco:phase "3" ;
  schema:startDate "2018-12-30" ;
  onco:related <https://onco.cc/trials/astrum-005/>, <https://onco.cc/trials/impower133/>, <https://onco.cc/trials/caspian/> ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:institutions <https://onco.cc/institutions/jilin-cancer-hospital/> ;
  onco:people <https://onco.cc/people/cheng-ying/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-capstone-1-lancet-oncol-2022/> .